VBI sells vac­cine and fa­cil­i­ty for $33M; Bay­er gets ra­dioiso­topes from Pan­Tera; Ther­mo Fish­er’s PPD ex­pands of­fer­ings

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

VBI Vac­cines is sell­ing its HBV vac­cine as­set VBI-2601 and its fa­cil­i­ty in Re­hovot, Is­rael, to Brii Bio­sciences for $33 mil­lion, it an­nounced on Wednes­day. The two com­pa­nies pre­vi­ous­ly ex­tend­ed their HBV part­ner­ship in Ju­ly last year to de­vel­op VBI-2601. Brii will now al­so gain the rights to de­vel­op and com­mer­cial­ize VBI-2601 in Asia Pa­cif­ic, apart from Japan. The deal is pre­dict­ed to close at the end of June this year. Both com­pa­nies will work to trans­fer man­u­fac­tur­ing to a site cho­sen by Brii Bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER